# Future Trends

By [DYLIT Chronicles](https://dylit.info/user/dylitmediabuzz)

[Everything AI](https://dylit.info/pr/everything-ai/6a9efac02e92664f4d50cf9d) > [Future Trends](https://dylit.info/ch/future-trends/6a9efac02e92664f4d50cfb6)

Anthropic Sets Up Biology Lab as Its AI Drug Work Expands What was reported Anthropic has built a wet lab, a facility for physical experiments, in the San Francisco Bay Area. Reuters reported the news on Sept. 18, citing two people familiar with the matter and describing the setup as quiet. Eric Kauderer-Abrams, Anthropic's head of life sciences, confirmed the lab in a Tuesday interview. What the lab will do Kauderer-Abrams said the final test in biology is still real lab work, and that Anthropic does some of it in-house and some with outside partners. A spokesperson said the lab isn't for drug discovery specifically and declined to elaborate. One source told Reuters the company wants Claude to direct robotic equipment with limited human intervention, an effort Kauderer-Abrams put in the "very early innings." In August, Anthropic released a Model Hardware Standard meant to help AI systems operate lab equipment. Why it matters The lab takes Anthropic's biology work beyond computer-based evaluation. At a June 30 event, the company launched Claude Science, a research workbench, and said it would pursue its own programs in neglected diseases that traditional drugmakers tend to skip. Kauderer-Abrams told Reuters that life sciences is now among Anthropic's largest areas by headcount and resources. Which diseases it targets, and how far along it is, remain unclear. Most drugs fail in trials, and Anthropic says it isn't running any for now. Partners and business context Anthropic bought the startup Coefficient Bio in April, reportedly for about $400 million in stock. It confirmed the acquisition and declined to comment on the price. It also added Novartis CEO Vas Narasimhan to its board and supplies tools to Genentech, Bristol Myers Squibb and Novo Nordisk, which announced its own deal with Anthropic this week. Kauderer-Abrams said Anthropic isn't competing with companies that bring drugs to market. Reuters reported that customers may still worry Anthropic could learn from their programs, even though it walls off their data. Safety and open questions The news arrives amid public unease about AI. Reuters noted that Anthropic recently said it found examples of its systems being usable toward biological weapons development, and that CEO Dario Amodei called for slowing AI development. A spokesperson said human oversight remains essential. On Sept. 17, Anthropic launched a Life Sciences Verification Program, giving vetted researchers models with adjusted safeguards and monitoring their use. The reports don't describe the lab's own biosafety measures. Sources Anthropic, "Introducing the Life Sciences Verification Program," Sept. 17, 2026: https://www.anthropic.com/news/life-sciences-verification-program MIT Technology Review, "Claude Science is Anthropic's newest flagship product," June 30, 2026: https://www.technologyreview.com/2026/06/30/1139987/claude-science-is-anthropics-newest-flagship-product/ Related YouTube videos "Introducing Claude for Life Sciences" (Oct. 20, 2025, features Anthropic's Jonah Cool and Eric Kauderer-Abrams): https://www.youtube.com/watch?v=sHImlfVM9r4 "Anthropic launches Claude Science, a dedicated app for scientists" (June 30, 2026): https://www.youtube.com/watch?v=0ynelBR8woY